Pfizer stock inched down Tuesday on a mixed first-quarter report. Sales missed, but cost cutting led to strong earnings.

Rimegepant 75mg; orally disintegrating tabs (ODT). Concomitant strong CYP3A4 inhibitors: Avoid use with Nurtec ODT. Concomitant moderate CYP3A4 inhibitors: Avoid another dose of Nurtec ODT within ...

Currently, AbbVie’s Ubrelvy (ubrogepant) and Pfizer’s Zavzpret (zavegepant) and Nurtec (rimegepant) are available for acute treatment in the US. To intensify the competition, novel drug combinations ...

The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Pfizer's earlier buy-in only gave it ex-US rights to rimegepant, already approved and on sale in the US as Nurtec ODT, so taking control of the entire company will give it full ownership of the ...

Jared S. Hopkins is a New York-based reporter for The Wall Street Journal, where he covers healthcare and pharmaceutical ...

Dr. Coric successfully led Biohaven through the FDA approval and launch of Nurtec ODT for the treatment of migraine. Under his leadership, the company also filed an NDA for its second drug ...

During her time there, she contributed toward the development of the manufacturing route and process for the drug substance of Nurtec® ODT, which was ultimately acquired by Biohaven. After moving to ...

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately.